Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 80 EV-to-EBITDA is 17.34 as of Jul. 16, 2026, which is 49% below its 10-year median of 34.30. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.05 (Fairly Valued). The stock has 1 warning sign investors should review. Among 507 Healthcare Providers & Services companies, Diaceutics ranks worse than 71.99% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Diaceutics's enterprise value is $143.21 Mil.
Diaceutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $8.26 Mil. Therefore, Diaceutics's EV-to-EBITDA for today is 17.34.
The historical rank and industry rank for Diaceutics's EV-to-EBITDA or its related term are showing as below:
DIUXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.06 Med: 34.3 Max: 505.92
Current: 18.54
During the past 10 years, the highest EV-to-EBITDA of Diaceutics was 505.92. The lowest was 13.06. And the median was 34.30.
DIUXF's EV-to-EBITDA is ranked worse than 71.99% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 11.03
vs DIUXF: 18.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Diaceutics (OTCPK:DIUXF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diaceutics's share price for today is $2.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Diaceutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diaceutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diaceutics's EV-to-EBITDA falls into.
Diaceutics's current Enterprise Value is $143.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $8.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (DIUXF) has a EV-to-EBITDA of 17.34 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diaceutics. This is 49% below median its historical median of 34.30. Over the past decade, Diaceutics' EV-to-EBITDA has ranged from 13.06 to 505.92. According to the industry distribution chart, Diaceutics ranks #365 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 72%.
Is Diaceutics' EV-to-EBITDA too high?
Diaceutics' current EV-to-EBITDA of 17.34 is 49% below median its 10-year median of 34.30. Over the past 10 years, this metric has ranged from a low of 13.06 to a high of 505.92. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.03. Diaceutics' value of 17.34 is 57.2% above this industry median. Based on the distribution chart, Diaceutics ranks #365 out of 507 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #365 out of 507 companies for EV-to-EBITDA. This places Diaceutics in the lower half of its industry. The industry median EV-to-EBITDA is 11.03. Diaceutics' value of 17.34 is 57.2% above this benchmark. Historically, Diaceutics' own EV-to-EBITDA has ranged from 13.06 to 505.92 over the past decade. While the company's 10-year median is 34.30 vs. the industry median of 11.03, Diaceutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.03, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current EV-to-EBITDA of 17.34 is 57.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diaceutics. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current EV-to-EBITDA is 17.34, which is 49% below median its own 10-year median of 34.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.05, compared to a current price of $2.00 — trading 2.4% below its estimated fair value. The current EV-to-EBITDA is 17.34, which is 49% below median its 10-year median of 34.30 and 57.2% above the Healthcare Providers & Services industry median of 11.03. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Diaceutics (DIUXF), the current EV-to-EBITDA is 17.34 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 2.4% below its estimated GF Value™ of $2.05.
GuruFocus considers Diaceutics to be Fairly Valued.
Key valuation signals for DIUXF:
EV-to-EBITDA: 17.34 (49% below median its 10-year median of 34.30)
GF Value™: $2.05 vs. price of $2.00 (2.4% below fair value)
Industry Position: 57.2% above the Healthcare Providers & Services median (#365 of 507)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score
Get the complete analysis for DIUXF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
